BTIG Research Reaffirms Buy Rating for Galapagos (GLPG)
BTIG Research reaffirmed their buy rating on shares of Galapagos (NASDAQ:GLPG) in a research note published on Thursday. They currently have a $118.00 price target on the biotechnology company’s stock.
A number of other equities analysts have also weighed in on the company. ValuEngine raised Galapagos from a sell rating to a hold rating in a research note on Friday, February 2nd. BidaskClub raised Galapagos from a hold rating to a buy rating in a research note on Wednesday, January 31st. Zacks Investment Research lowered Galapagos from a hold rating to a strong sell rating in a research note on Thursday, January 25th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $120.00 price target on shares of Galapagos in a research note on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. Galapagos presently has a consensus rating of Buy and an average target price of $111.00.
Galapagos (NASDAQ:GLPG) opened at $108.83 on Thursday. The firm has a market capitalization of $5,543.47, a price-to-earnings ratio of -118.29 and a beta of 1.85. Galapagos has a 12 month low of $67.26 and a 12 month high of $121.09.
COPYRIGHT VIOLATION NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.thecerbatgem.com/2018/02/12/btig-research-reaffirms-buy-rating-for-galapagos-glpg.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.